Please login to the form below

Not currently logged in
Email:
Password:

Sarepta Therapeutics

This page shows the latest Sarepta Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m. ... Sarepta is looking to deepen its presence in gene therapy with a new licensing deal with Lacerta Therapeutics.

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics. ... Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in the competition to hustle ahead new DMD drugs to regulators. ... This month also saw CAR-T “ wunder-kid” Juno Therapeutics

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Minoryx Therapeutics adds to board of directors Minoryx Therapeutics adds to board of directors

    Dr Claude Nicaise has joined Barcelona, Spain-based Minoryx Therapeutics as an independent board member. ... He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist, and currently also serves as a board member at

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics. ... Procter &Gamble. Reckitt Benckiser. Regeneron. Replicel. Roche. RPS. Sanofi. Santen. Sarepta Therapeutics.

  • Random42 Scientific Communication

    Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics. ... Procter &Gamble. Reckitt Benckiser. Regeneron. Replicel. Roche. RPS. Sanofi. Santen. Sarepta Therapeutics.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics